Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but it's expensive.
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...
The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...
A chocolate recall was recently upgraded to warn consumers of a potential to “cause serious adverse health consequences of death.” ...
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
The list of recalled food products being elevated to Class I (the highest recall level) by the U.S. Food and Drug Administration (FDA) is continuing to grow. This time, the organization has updated ...
Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way for the rollout of a product that has simultaneously sparked high hopes and ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
What will the industry face or achieve in 2025? These trends will be critical in medical device cybersecurity.
The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.
There is no evidence that a senior Food and Drug Administration (FDA) worker was arrested after samples of the H5N1 bird flu virus were found in his fridge. The narrative stems from a website whose ...
It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.